decrease font size
increase font size
change type face
bookmark this page
email this page
print this page
Latest Pig Industry News
Wednesday, May 02, 2007
Print This Page Circovirus Vaccine Receives Four-Month Duration of Immunity Approval
US - Boehringer Ingelheim Vetmedica, Inc., (BIVI) has announced that the U.S. Animal and Plant Health Inspection Service has approved a duration of immunity (DOI) claim for Ingelvac® CircoFLEX™ of at least four months for porcine circovirus type 2 (PCV2), the primary pathogen for porcine circovirus associated disease (PCVAD).
According to Klaas Okkinga, marketing manager for Boehringer Ingelheim, the approved DOI label extension substantiates extensive research findings that Ingelvac CircoFLEX provides long-lasting protection from PCV2.
"A vaccine that provides at least four months of PCV2 immunity is a significant benefit to producers in protecting pigs, both early and late, from damage caused by this disease," says Okkinga.
"Currently, Ingelvac CircoFLEX is the only PCV2 vaccine available with proven DOI of this length when administered as a single-dose to pigs 3 weeks of age or older," Okkinga adds.
"Even when administered early, it still protects through the critical period in grow-finish, resulting in reduced pig mortality and improved performance."
| ThePigSite News Desk | Read more Boehringer Ingelheim News here |
More of the latest Pig Industry News
Strong CAP Needed to Help Europe Grow
Feed Segment Still Key for DaChan
Report Highlights Impacts of Livestock Production- Agriculture a Key Area for NPC
US Pork Exports to Mexico Thriving
Bringing Home the Bacon – At Last!
Connecting Urban Public to Agriculture
UK Slaughter Statistics - March 2010- CME: US Trade Officials Attempt to Seal Pork Deal
- BIVI Announces 2010 PRRS Research Award Recipients
